BTAI Earnings

BTAI reported its earnings on 2026-03-16, showcasing a revenue of against an estimate of 200.00K, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.34 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following BTAI's earnings announcement on 2026-03-16, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, BTAI's stock price tends to shift by an average of 10.21% in the 10 days leading up to earnings and -10.85% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate BTAI's annual revenue to reach 166.67K, while the EPS is projected at -0.75. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between BTAI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, BTAI's stock price typically moves by 10.21% in the 10 days before its earnings and -10.85% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.75 and revenue of 166.67K.

The earnings call highlights financial strain with declining IGALMI revenue, a significant net loss, and increased COGS due to inventory issues. Although R&D and other expenses have decreased, the company faces regulatory risks and competitive pressures. The Q&A section reveals management's lack of clarity on FDA feedback and financial sufficiency, which raises concerns. Despite some progress in trials and reduced losses, the absence of a shareholder return plan and unclear guidance suggest a negative market reaction.